Skip to main navigation Skip to search Skip to main content

Transitioning from parenteral treprostinil to inhaled treprostinil in patients with pulmonary arterial hypertension

  • Amresh Raina
  • , James C. Coons
  • , Manreet Kanwar
  • , Srinivas Murali
  • , George Sokos
  • , Raymond L. Benza

Research output: Contribution to journal › Article › peer-review

Abstract

Treprostinil is a potent prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH, World Health Organization Group I). Previously, treprostinil was available only in subcutaneous (SC) or intravenous (IV) formulations. Availability of an inhaled formulation of treprostinil has provided clinicians with an alternative to continuous SC or IV treprostinil in appropriate patients. Stable PAH patients whose quality of life has been dramatically impacted by side effects of parenteral therapy or those who have had recurrent, life-threatening bloodstream infections but are otherwise responding well to treatment may be the candidates for continuing prostacyclin therapy with inhaled treprostinil. However, there is little clinical experience with transitioning patients from parenteral to inhaled treprostinil. We present the results of two cases that highlight important considerations in transitioning patients from parenteral to inhaled therapy, including the pharmacologic and clinical equivalence of formulations, dose titration of formulations and suggested criteria for patient selection.

Original languageEnglish
Pages (from-to)116-120
Number of pages5
JournalPulmonary Circulation
Volume3
Issue number1
DOIs
StatePublished - Jan 2013

Keywords

  • Case study
  • Prostacyclin
  • Prostanoid
  • Pulmonary arterial hypertension
  • Transition
  • Treprostinil

Fingerprint

Dive into the research topics of 'Transitioning from parenteral treprostinil to inhaled treprostinil in patients with pulmonary arterial hypertension'. Together they form a unique fingerprint.

Cite this